Salum J Lidenge
Overview
Explore the profile of Salum J Lidenge including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
21
Citations
380
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Mukasine M, Mulundu G, Kawimbe M, Mutale K, Mumba C, Lidenge S, et al.
Trop Med Infect Dis
. 2024 Jun;
9(6).
PMID: 38922046
Kaposi sarcoma (KS) is an AIDS-defining angio-proliferative malignancy, with the Kaposi sarcoma-associated herpes virus (KSHV) as its etiologic agent. Upon treatment with chemotherapy, a proportion of HIV-associated KS patients experience...
2.
Lidenge S, Yalcin D, Bennett S, Ngalamika O, Kweyamba B, Mwita C, et al.
Viruses
. 2024 Mar;
16(3).
PMID: 38543814
Seasonal coronaviruses (HCoVs) are known to contribute to cross-reactive antibody (Ab) responses against SARS-CoV-2. While these responses are predictable due to the high homology between SARS-CoV-2 and other CoVs, the...
3.
Bennett S, Yalcin D, Privatt S, Ngalamika O, Lidenge S, West J, et al.
PLoS Pathog
. 2024 Feb;
20(2):e1012023.
PMID: 38381773
Protein-level immunodominance patterns against Kaposi sarcoma-associated herpesvirus (KSHV), the aetiologic agent of Kaposi sarcoma (KS), have been revealed from serological probing of whole protein arrays, however, the epitopes that underlie...
4.
Privatt S, Braga C, Johnson A, Lidenge S, Berry L, Ngowi J, et al.
Cancer Metab
. 2023 Aug;
11(1):13.
PMID: 37653396
Background: Kaposi sarcoma (KS) is a neoplastic disease etiologically associated with infection by the Kaposi sarcoma-associated herpesvirus (KSHV). KS manifests primarily as cutaneous lesions in individuals due to either age...
5.
Mduma E, Dharsee N, Samwel K, Mwita C, Lidenge S
JCO Glob Oncol
. 2023 May;
9:e2200394.
PMID: 37216622
Purpose: In the past 20 years, the burden of anal cancer (AC) increased by 60% in the United States and over three-fold in Africa. Rates of AC have increased by...
6.
Bennett S, Yalcin D, Privatt S, Ngalamika O, Lidenge S, West J, et al.
PLoS Pathog
. 2022 Dec;
18(12):e1011033.
PMID: 36534707
The humoral antibody response against Kaposi sarcoma-associated herpesvirus (KSHV) in infected individuals has been characterized demonstrating the latency-associated nuclear antigen (LANA) as the most antigenic KSHV protein. Despite the antigenicity...
7.
Ngalamika O, Lidenge S, Mukasine M, Kawimbe M, Kamanzi P, Ngowi J, et al.
Int J Infect Dis
. 2022 Dec;
127:106-115.
PMID: 36516914
Objectives: To longitudinally compare SARS-CoV-2-specific T cell and humoral immune responses between convalescent individuals who are HIV-positive (HIV+) and HIV-negative (HIV-). Methods: We conducted enzyme-linked immunospots to determine the SARS-CoV-2-specific...
8.
Tso F, Lidenge S, Ngowi J, Pena P, Clegg A, Ngalamika O, et al.
J Clin Med
. 2022 Aug;
11(15).
PMID: 35956046
Background: Despite the high COVID-19 morbidity and mortality rates across the world, the reported rates in sub-Saharan Africa (SSA), which has a higher burden of other infectious diseases and overwhelmed...
9.
Ngalamika O, Mukasine M, Kamanzi P, Kawimbe M, Mujajati A, Tso F, et al.
J Immunol Res
. 2022 Aug;
2022:2114285.
PMID: 35935575
Severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) virus is the cause of coronavirus disease 2019 (COVID-19). It has caused millions of infections and deaths globally over a 2-year period....
10.
Tso F, Lidenge S, Poppe L, Pena P, Privatt S, Bennett S, et al.
PLoS One
. 2021 Mar;
16(3):e0247640.
PMID: 33661923
Background: Neutralizing-antibody (nAb) is the major focus of most ongoing COVID-19 vaccine trials. However, nAb response against SARS-CoV-2, when present, decays rapidly. Given the myriad roles of antibodies in immune...